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Key Points




A single-institution
experience with
G-CSF and ﬁve
alternative PB
mobilization strategies
in related allogeneic
donors.
Machine learning
models were
established to predict
G-CSF–induced PB
mobilization in
allogeneic donors
with an accuracy of
up to 83%.

Mobilized peripheral blood has become the primary source of hematopoietic stem cells for
both autologous and allogeneic stem cell transplantation. Granulocyte colony-stimulating
factor (G-CSF) is currently the standard agent used in the allogeneic setting. Despite the
high mobilization efﬁcacy in most donors, G-CSF requires 4–5 days of daily administration,
and a small percentage of the donors fail to mobilize an optimal number of stem cells
necessary for a safe allogeneic stem cell transplant. In this study, we retrospectively
reviewed 1361 related allogeneic donors who underwent stem cell mobilization at
Washington University. We compared the standard mobilization agent G-CSF with ﬁve
alternative mobilization regimens, including GM-CSF, G-CSF1GM-CSF, GM-CSF 1 Plerixafor,
Plerixafor and BL-8040. Cytokine-based mobilization strategies (G-CSF or in combination
with GM-CSF) induce higher CD34 cell yield after 4–5 consecutive days of treatment, while
CXCR4 antagonists (plerixafor and BL-8040) induce signiﬁcantly less but rapid mobilization
on the same day. Next, using a large dataset containing the demographic and baseline
laboratory data from G-CSF–mobilized donors, we established machine learning
(ML)–based scoring models that can be used to predict patients who may have less than
optimal stem cell yields after a single leukapheresis session. To our knowledge, this is the
ﬁrst prediction model at the early donor screening stage, which may help identify
allogeneic stem cell donors who may beneﬁt from alternative approaches to enhance stem
cell yields, thus ensuring safe and effective stem cell transplantation.

Introduction
Peripheral blood (PB) has largely replaced bone marrow as the predominant source of hematopoietic
stem cells (HSCs) for hematopoietic stem cell transplantation (HSCT).1 In healthy donors, HSC
mobilization is generally induced by 4-5 days consecutive daily doses of 10 mg/kg subcutaneously (SC)
of granulocyte colony-stimulating factor (G-CSF).2 While G-CSF is effective and is the standard of care
for stem cell mobilization in the allogeneic setting, other mobilization strategies such as granulocytemacrophage colony-stimulating factor (GM-CSF), CXCR4 antagonists or the combination of both cytokine and CXCR4 antagonists have been evaluated in clinical trials to assess their efﬁcacy in stem cell
mobilization.3 Plerixafor, a selective CXCR4 antagonist that reversibly competes and binds to CXCR4, is
one of the ﬁrst agents approved for stem cell mobilization in the autologous setting.4,5 Other peptide
CXCR4 antagonists, such as BL-8040 (Motixafortide), also induce rapid stem cell mobilization in healthy
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volunteers and allogeneic stem cell donors.6 This report summarizes
one of the largest single-institution experiences with stem cell mobilization of related allogeneic donors with multiple cytokines, chemokine antagonists and cytokine/chemokine antagonist combinations.

In recent years, with the increasing amount and complexity of patient
data, machine learning (ML) has become popular due to its ability to
quickly analyze large complex datasets and recognize the intrinsic
pattern within the input data.13 ML has also been used in the context of HSCT, for example, to predict acute graft-versus-host disease following allogeneic transplantation.14 Nevertheless, ML-based
prediction of stem cell mobilization has not been explored yet.
In this study, we retrospectively reviewed 1361 related allogeneic
healthy donors from Washington University (WU) Blood and Marrow Transplant (BMT) program from 1995 to 2018. We compared
the impact of 6 mobilization strategies on their efﬁcacy to mobilize
stem cells in allogeneic donors. Using demographic data and baseline screening laboratory results from the G-CSF–mobilized normal
donors, we established ML-based scoring models to predict donors
who may have poor/suboptimal stem cell yield (CD34 cell count
,40/mL) following standard G-CSF. We expected that this
machine learning approach would enable us to detect donors with
suboptimal mobilization response at the early donor screening
stage, at a time when potentially alternative approaches could be
pursued to ensure optimal stem cell yields for HSCT. These alternative approaches may include selecting alternative related donors if
available, increasing dose or frequency of G-CSF dosing, the addition of chemokine antagonists or GM-CSF to G-CSF.

Methods
Patient population
The Washington University School of Medicine institutional review
board approved this retrospective study. The study was conducted
in accordance with the Declaration of Helsinki. We retrospectively
reviewed 1361 related allogeneic adult ($18 years old) stem cell
donors who underwent stem cell mobilization at WU Siteman Cancer Center between 1995 and 2018. Donors were mobilized with
the standard of care G-CSF (G, N 5 1025) or various other mobilization strategies evaluated through phase I/II clinical trials at Washington University, including: GM-CSF (GM, N 5 40), G-CSF 1
GM-CSF (G1GM, N 5 167), GM-CSF 1 Plerixafor (GM1P, N 5
23), Plerixafor (N 5 88) and BL-8040 (N 5 18).

Mobilization regimens
Cytokine-based mobilization agents including G-CSF or GM-CSF
involve 4–5 days of consecutive treatment before apheresis and
stem cell collection, whereas CXCR4 antagonists (Plerixafor and
1992
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Data collection
Donor demographics, including age at donation, gender, BMI at
baseline, and donor baseline laboratory results (supplemental Table
1), including CBC with differential, blood chemistry was collected
by retrospective chart review in electronic health record (EHR). Day
1 (of LP) CD34 yield per kg of the recipient body weight and PB
CD34 count/mL were collected from EHR as the primary outcomes
of the study. Protected health information (PHI) was removed before
proceeding to the subsequent modeling analysis.

Machine learning modeling
The modeling process was implemented in Scikit-learn.17 Data from
799 G-mobilized donors (Figure 2) were used to establish the predictive models for stem cell mobilization. The binary outcome of the
prediction model was deﬁned as on day 1 of LP: (1) class 0, donors
who failed to reach the goal of optimal stem cell mobilization of 40
cells/mL (poor/less-than-optimal mobilizer); (2) class 1, donors who
reached the optimal stem cell mobilization of 40 cells/mL (good
mobilizer). One donor with missing CD34 count was manually
assigned to the good mobilizer category based on the corresponding day 1 CD34 collection yield. Raw data underwent several preprocessing steps, including data normalization, mobilization class
mapping and class distribution rebalancing with the synthetic minority oversampling technique (SMOTE) algorithm (described separately below). To obtain stable prediction models, different
xi 2minðxÞ
,
demographic features are linearly normalized by: zi ¼ maxðxÞ2minðxÞ
th
where xi represents the feature value of the i donor, minðxÞ and
max ðxÞ are the minimum and maximum across all feature values
under feature x.
Subsequently, different prediction methods were established, including a feature selection process to achieve improved results. In addition, a grid searching process is used to automatically select
appropriate hyper-parameters for each prediction model. Seven
machine learning algorithms, including Decision Tree, Linear Regression, Random Forest, Support Vector Machine, Feedforward Neural
Networks, AdaBoost and Gradient boosting, were adopted to build
the prediction model. Each model was trained and validated using
12 APRIL 2022 • VOLUME 6, NUMBER 7
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It is widely accepted that a minimum of 2 3 106 cells/kg of recipient body weight is needed to ensure multilineage engraftment in
recipients.7 The optimal number of stem cells is 5 3 106 cells/kg,
which leads to earlier and more consistent neutrophil and platelet
engraftment and reduced resource utilization.8 Remobilization is
costly, and stem cell yield is usually less than the initial mobilization.9
Several algorithms have shown success in predicting and preventing mobilization failure through the preemptive approach based on
well-established post-mobilization PB CD34 count and stem cell
yield. Most of these focus on the pre-apheresis stage after the mobilization regimen has been completed but before apheresis.10-12

BL-8040) induce a rapid mobilization of stem cells, and the apheresis is completed in the same day. The standard mobilization regimen
G-CSF was administered at 10 mg/kg SC once daily with leukapheresis (LP) commencing on day 5. Administration of GM and G1GM
were described previously15: GM alone was administered at 10 or
15 mg/kg SC once daily with LP commencing on day 6; in the
G1GM cohort, G (10 mg/kg) and GM (5 mg/kg) were administered
SC once daily with LP commencing on day 5. In the GM1P cohort
(ClinicalTrials.gov Identiﬁer: NCT01158118), GM was administered
at 5 mg/kg SC once daily with one dose of Plerixafor at 320 mg/kg
IV before the LP on day 5. In the Plerixafor alone cohort, Plerixafor
was administered at 320 mg/kg IV (ClinicalTrials.gov Identiﬁer:
NCT00914849) or 240 mg/kg by one SC dosing (ClinicalTrials.gov
Identiﬁer: NCT01696461), LP was commenced 4 hours post mobilization. In our analysis, donors receiving either SC or IV of Plerixafor
were combined into one cohort as previous studies from our group
showed that SC or IV administration of Plerixafor had similar mobilization kinetics and efﬁcacy.16 In the BL-8040 cohort (ClinicalTrials.
gov Identiﬁer: NCT02639559), a single dose of BL-8040 was
administered at 1.25 mg/kg by SC, and LP was commenced 3
hours (up to 270 minutes) post mobilization.

Table 1. Patient characteristics of 1361 related allogeneic donors
Regimens

Age

All patients

Total, N

1361

Median (range)

49 (18-79)

Sex, n (%)

Race, n (%)

G-CSF 1 GM-CSF

1025
50 (18-78)

GM-CSF

167
44 (18-77)

GM-CSF 1 Plerixafor

40

Plerixafor

23

49 (29-79)

BL-8040

88

52 (21-65)

18

51 (21-67)

55 (20-69)

Female

611 (44.9)

462 (45.1)

74 (44.3)

19 (47.5)

13 (56.5)

36 (40.9)

7 (38.9)

Male

750 (55.1)

563 (54.9)

93 (55.7)

21 (52.5)

10 (43.5)

52 (59.1)

11 (61.1)

White

1209 (88.8)

904 (88.2)

148 (88.6)

38 (95)

21 (91.3)

82 (93.2)

16 (88.9)

African American
Others
Unknown

96 (7.1)

78 (7.6)

41 (3)

31 (3)

15 (1.1)

10 (6)

12 (1.2)

Day 1 CD34 per kg (106)

6.97 (0.1-62.65)

7.57 (0.3-62.65)

Day 1 CD34 per mL

64 (0.5-528)

70 (4.6-503)

1 (2.5)

1 (0.6)

2 (8.7)

5 (5.7)

—

1 (1.1)

—

8 (4.8)

—

—

2.82 (0.79-15.41)

2.27 (0.2-19.73)

1 (2.5)

7.6 (0.3-57.4)

2.9 (0.1-20.6)

79.7 (1.5-528)

26 (0.5-150)

—
1 (5.6)

23 (8-144)

1 (5.6)

16 (2-107)

2.25 (0.4-9.42)
27 (6-50)

10-fold cross-validation. Finally, the prediction performance of different methods was compared using accuracy, F1 score, and area
under the ROC curve (AUC) metrics; and the prediction scores of
each donor belonging to the 2 classes of “less-than-optimal mobilizer” and “good mobilizer” were generated as the output of the prediction model. A threshold of 0.5 was adopted to classify the donor
as good mobilizer (mobilization score . 0.5) or poor/less-than-optimal mobilizer (mobilization score , 0.5).18 Detailed description for
each individual algorithm is included in the supplemental Methods.

described by AUC. Data analyses were performed using SAS 9.4
(SAS Institutes, Cary, NC) for logistic regression and using Prism
8 (GraphPad Software, Inc.) and Statistics (IBM) for all others.
Results were considered to reach signiﬁcance at P # .05 and are
indicated with asterisks (*P # .05; **P # .01; ***P # .001; ****P #
.0001). The source code used in our ML modeling is deposited and
maintained on GitHub website (https://github.com/MollahLab/
PBHSCM).

Oversampling with SMOTE

Results

Since the donor distribution in class 0 and class 1 are highly
skewed (1:3.7, class 0 is a minority while class 1 is a majority), this
constitutes to a class imbalance problem.19 To mitigate this problem, we performed a class distribution rebalancing process using
SMOTE.20 SMOTE is an over-sampling method in which the minority class is over-sampled by creating “synthetic” samples. Using
SMOTE, 458 minority samples were synthesized and added to
class 0.

Allogeneic donor characteristics

Statistical analysis
Descriptive statistics were used to examine the patient’s basic characteristics and proportion of different mobilization efﬁciency. Inferential statistics between different mobilization strategies were
performed using nonparametric Kruskal-Wallis tests. The Pearson
correlation coefﬁcient test was adopted to determine statistically signiﬁcant correlations between the 2 groups. As a comparison, a conventional multivariate logistics regression (good mobilization or not)
was also constructed using the least absolute shrinkage and selection operator (LASSO). The linearity of each predictor was assessed
by generalized additive models using nonparametric smoothing
splines. The model performance was validated using 10-fold crossvalidation. Odds ratios (OR) and their 95% conﬁdence intervals
were used to summarize the strength of association between each
predictor and outcome. The predictive ability of the model was

We identiﬁed 1361 related healthy adult ($18 years old) stem cell
donors who underwent their ﬁrst stem cell mobilization at the BMT
program of Washington University from 1995 to 2018. The baseline
donor characteristics are shown in Table 1. The median age of all
donors at the time of mobilization was 49 (range: 18-79). Age was
comparable between different mobilization regimens, except that the
donors in the G1GM cohort were signiﬁcantly younger than the
G-alone group (P , .0001, Kruskal-Wallis test) and Plerixafor alone
group (P 5 .0075, Kruskal-Wallis test). The majority of the donors
(N 5 1025, 75.3%) were mobilized with the standard mobilization
agent G-CSF. 336 healthy adult donors participated in the clinical
trials (detailed in the methods) of alternative allogeneic mobilization
strategies including: GM-CSF (N 5 40, 2.9%), Plerixafor (N 5 88,
6.5%), BL-8040 (N 5 18, 1.3%), G-CSF 1 GM-CSF (N 5 167,
12.3%) and GM-CSF 1 Plerixafor (N 5 23, 1.7%). 611 (44.9%) of
the donors were female, and 750 (55.1%) of the donors were male.
The percentage of female donors was highest in the GM 1 Plerixafor (56.5%) cohort and lowest in the BL-8040 cohort (38.9%). The
race of the majority of the donors was White, comprising 88.8% of
all donors and ranging from 88.2% to 95% in each treatment
group. The race of the rest of the donors was African American
(N 5 96, 7.1%), others (N 5 41, 3%), and unknown (N 5 15,

Table 2. Deﬁnition of “poor,” “less-than-optimal,” and “good” mobilizer
Day 1 CD34 yield/kg

Day 1 CD34/mL

Day 1 CD34/mL

Day 1 CD34 yield/kg (106)
9.03 (0.77-62.65)

Good, $5 3 10 /kg

87 (29-503)

Good ($40)

Less-than-optimal, 2-5 3 106/kg

36 (7-144)

Less-than-optimal (20-40)

Poor, #2 3 10 /kg

18 (4.6-174)

6

6
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Poor (#20)

3.48 (0.7-8.9)
1.7 (0.3-3.65)
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BL-8040
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80

-200

56.5%
44.4%
51.1%

73.9%

Plerixafor

G-CSF

GM-CSF + Plerixafor (n = 23)
BL-8040 (n = 18)
Plerixafor (n = 88)

≥5 x106

PB CD34 count/µL

100

GM-CSF

GM-CSF (n = 40)

Day 1 CD34 (x106) per kg of body weight

PB CD34 count/µL

GM-CSF + Plerixafor

2-5 x106

G-CSF (n = 1025)

≤20

20-40

G-CSF + GM-CSF (n = 167)
G-CSF (n = 1023)
GM-CSF (n = 40)
GM-CSF + Plerixafor (n = 23)
BL-8040 (n = 18)
Plerixafor (n = 88)

≥40

Day 1 peripheral blood CD34 /µL

Figure 1. Impact of mobilization strategies on normal donor stem cell yield. Allogeneic donors were mobilized with cytokine (G-CSF or GM-CSF or G-CSF1GMCSF), CXCR4 antagonists (Plerixafor or BL-8040) or combination of cytokine and CXCR4 antagonist (GM-CSF1Plerixfor). (A) Day 1 (of apheresis) CD34 stem cell yield
per kg of recipient body weight in donors mobilized with different mobilization regimens. (B) Percentage of “poor mobilizer” (#2 3 106 cells/kg), “less-than-optimal mobilizer”
(2-5 3 106 cells/kg), and “good mobilizer” ($5 3 106 cells/kg) in different mobilization regimens. (C) Day 1 peripheral blood (PB) CD34 cell count/mL in donors mobilized
with different mobilization regimens. (D) Percentage of “poor mobilizer” (PB CD34 count #20/mL), “less-than-optimal” (PB CD34 count 20-40/mL), and “good mobilizer”
(PB CD34 count $40/mL) in different mobilization regimens.

The minimum threshold of CD34 stem cells for transplantation is
2 3 106/kg, below which is deﬁned as a “poor mobilizer.” The optimal dose is 5 3 106/kg, and donors who failed to reach this target
were deﬁned as “less-than-optimal mobilizer” (2-5 3 106/kg). However, the donor: recipient weight difference can vary greatly and
confound the analysis. Thus, we examined the equivalent PB CD34
count of “poor mobilizers,” “less-than-optimal mobilizers,” and “good
mobilizers” in our G-CSF cohort (N 5 1025). In G-CSF mobilized
donors (N 5 1023), PB CD34 count was strongly correlated with
the CD34 yield (r 5 0.81, P , .0001) (supplemental Figure 1). In
Table 2, we found that the median PB CD34 count is 18 cells/mL
in donors with less than 2 3 106/kg, which is in line with the 20
cells/mL that others have reported,7 and the median PB CD34
count for “less-than-optimal mobilizers” was 36 cells/mL. Using this
information, we deﬁned donors with day 1 PB CD34 count # 20
cells/mL as “poor mobilizers,” donors with day 1 CD34 count
between 20-40 as “less-than-optimal mobilizers” and donors with
day 1 CD34 count $ 40 as “good mobilizers.”

(both G-CSF alone or G 1 GM) induced signiﬁcantly higher CD34
cells/kg (P , .0001) than any of the other groups. In line with this
ﬁnding, the majority of the donors mobilized with G-CSF alone
(71.1%) and G 1 GM (74.9%) had good mobilization (. 5 3 106/
kg), with failure rates only 5.4% and 4.8% in the G-CSF or GM
mobilized donors, respectively (Figure 1B). In contrast, single-day
mobilization with CXCR4 antagonist alone (Plerixafor or BL-8040)
was associated with a high poor mobilizer rate ranging from 38.9%
to 42%. This was also consistent when the mobilizer status was
deﬁned by PB CD34 count per mL (Figure 1D). Interestingly,
although there was no statistical difference in CD34 yields (Figure
1A), there was a higher percentage of good mobilizers, and a lower
percentage of poor mobilizers from BL-8040 mobilized donors,
compared with Plerixafor. GM alone or in combination with Plerixafor
showed comparable efﬁcacy as the CXCR4 antagonists alone.
Together, these data showed that mobilization with G-CSF is effective, other mobilization strategies such as CXCR4 antagonists can
induce a rapid mobilization in one day, but they fail to induce minimum stem cell yields in 30% to 50% of the donors after a single
apheresis.

Impact of mobilization regimen on stem cell yield

Patient selection for ML modeling

We ﬁrst compared the day 1 CD34 yield of a single 20 L (median
collection volume) apheresis from the six different mobilization strategies. All of these mobilization agents were well-tolerated in patients.
Among six different mobilization approaches (Figure 1A,C), G-CSF

After removing donors with missing demographic or laboratory data,
799 G-CSF mobilized donors (from 2003 to 2018) were identiﬁed
for the predictive analysis (Figure 2), among which 171 donors had
CD34 count , 40/mL (poor/less-than-optimal mobilizer) and 628

1.1%). The median CD34 yield/kg was 6.97 3 106, and the median
PB CD34 count was 64 cells/mL on day 1 of LP.

1994
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0
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27.5%
39.1%
44.4%
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–20
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35.0%
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20

ns

G-CSF

60

4.8%
5.4%

****

GM-CSF

****

GM-CSF + Plerixafor

% of donors

BL-8040

32.5%
17.4%
38.9%
42.0%

Plerixafor

74.9%
71.1%

CD34 yield/kg
80

32.5%
26.1%
16.7%
6.8%

B

CD34 yield/kg

32.5%
17.4%
16.7%
4.5%

A

Identified G–CSF mobilized
related allogeneic donors
1025 donors

Missing BMI data
(–186 donors)
839 donors

799 donors

Prediction analysis
CD34 <40/µL vs CD34 ≥40 µL
Figure 2. Flow-chart of patient selection for the prediction analysis. One thousand twenty-ﬁve G-CSF mobilized allogeneic donors were identiﬁed in the EHR database. Donors with key demographical data (N 5 186) missing or incomplete donor screening laboratory test data (N 5 40) were removed. The remaining 799 donors were
selected for the subsequent prediction analysis to identify donors with “poor/less-than-optimal” mobilization (Day 1 PB CD34 cell count ,40/mL) or “good” mobilization
(Day 1 PB CD34 cell count $40/mL).

donors had CD34 count $ 40/mL (good mobilizer). Patient characteristics used in the predictive modeling were summarized in supplemental Table 1. 70.6% of the donors (N 5 564) were matched
siblings, and 29% were haplo-identical donors (N 5 232) (supplemental Table 2). From an initial assessment of the baseline laboratory and demographical data using Pearson correlation test from
these donors, we found that age and BMI, as well as basal laboratory results including WBC, platelet counts, lymphocyte count,
monocyte counts, uric acid and a few others, were signiﬁcantly correlated with the day 1 PB CD34 count (Table 3). This prompted us
to explore if we can use these data to predict donors who may have
poor or less-than-optimal mobilization (CD34 count , 40/mL) in
response to G-CSF at the early donor screening stage. We took
advantage of the large dataset of G-CSF-mobilized donors and
used a novel unbiased machine learning approach.

ML model predicts response to G-CSF-mediated
stem cell mobilization
We adopted a well-established machine learning pipeline (Figure
3A) to predict whether the donors may have poor or less-than-optimal mobilization (CD34 count , 40/mL), based on demographics
and baseline laboratory data. A tree-based feature selection
revealed 18 highly discriminant features for the linear regression and
decision tree models (Figure 3B). The top 3 variables also showed
signiﬁcant correlation with the day 1 CD34 count. There was a signiﬁcant negative correlation (r 5 20.25) between age and day 1
CD34 count (Figure 3C) and a positive correlation between platelet
count (r 5 0.21) and BMI (r 5 0.27) and day 1 CD34 count (Figure
3D-E). When stratiﬁed by BMI, overweight and obese donors had
signiﬁcantly higher CD34 yield (Figure 3F). These key clinical features, as well as the rest of the features, were adopted and the
12 APRIL 2022 • VOLUME 6, NUMBER 7

prediction models were developed using seven machine learning
algorithms. We then evaluated different models using a 10-fold
cross-validation technique: dataset containing all 799 donors were
ﬁrst partitioned into 10 equal-size subsets, then in each fold, a different subset was iteratively retained as the validation set while the
remaining 9 subsets were combined as the training set. The
Table 3. Top variables correlated with Day 1 PB CD34 count/mL
r

P, 2-tailed, P summary

PB CD34 count vs BMI

0.2744

,.0001****

PB CD34 count vs WBC

0.2303

,.0001****

PB CD34 count vs Platelets

0.2094

,.0001****

PB CD34 count vs Lymphs, absolute

0.1891

,.0001****

PB CD34 count vs Mono, absolute

0.1883

,.0001****

PB CD34 count vs Uric acid

0.1834

,.0001****

PB CD34 count vs Neutrophil, absolute

0.178

,.0001****

PB CD34 count vs RBC

0.1759

,.0001****

PB CD34 count vs ALT

0.1378

,.0001****

PB CD34 count vs BASO, absolute

0.1196

.0007***

Pearson correlation

PB CD34 count vs EOS, absolute

0.1139

.0013**

PB CD34 count vs MPV

0.09903

.0051**

PB CD34 count vs PTT

0.08833

.0126*

PB CD34 count vs Hematocrit

0.07807

.0274*

PB CD34 count vs BUN

20.1216

.0006***

PB CD34 count vs Age

20.2475

,.0001****

PB CD34 count vs MCV

20.1708

,.0001****

PB CD34 count vs MCH

20.1613

,.0001****
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Figure 3. Machine learning-based modeling to predict “poor/less-than-optimal” vs “good” mobilizer. (A) Schema of machine leaning modeling pipeline to
predict “poor/less-than-optimal” vs “good” mobilizer. (B) Tree-based feature selection for linear regression and decision tree modeling, ranked by feature importance. Correlation of age (C), platelet count (D), and BMI (E) with Day 1 PB CD34 count/mL; Day 1 PB CD34 count/mL in normal (BMI: 18.5-25), overweight (BMI: 25-30) and obese
(BMI: .30) donors (F); ROC curve of seven machine learning prediction algorithms, including: Decision tree, Linear Regression, Random Forest, Support Vector Machine,
Feedforward Neural Networks, AdaBoost and Gradient boosting (G). (H) Model performance evaluated by accuracy, F1 score, and AUC.

prediction abilities of seven produced prediction models were compared by the receiver operating characteristic (ROC) curves (Figure
3G). AUC is the gold standard to evaluate the predictive performance of the prediction models. We also used accuracy and F1
score to compare the average prediction results quantitatively over
the 10-fold runs (Figure 3H). According to all 3 metrics, Random
Forest and AdaBoost achieved the best performance, with AUCs of
0.89 and 0.88, respectively (Table 4).
Prediction scores for each donor in the validation cohort were calculated from the Random Forest or AdaBoost algorithms. The prediction score that predicts the good mobilizers was called the
“mobilization score,” which represented the likelihood of having
CD34 count $ 40 cells/mL. The higher the mobilization score, the
higher the likelihood the CD34 counts would be higher than 40
cells/mL, as shown in Figure 4A,D. In addition, we examined the
distribution of the mobilization scores for all 799 donors. Both
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Random Forest and AdaBoost based showed good discrimination
of good mobilizers vs less-than-optimal mobilizers (Figure 4B,E).
Finally, the performance of the two models with all 799 donors was
constructed in confusion matrices (Figure 4C,F). In the Random
Table 4. Table of AUCs from seven ML prediction models.
Machine learning algorithms

AUC

Decision tree

0.76

Linear regression

0.7

Random forest

0.89

Support vector machine

0.85

Feedforward neural network

0.83

Adaboost

0.88

Gradient boosting

0.61
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Figure 4. ML-based mobilization score predicts response to G-CSF-mediated stem cell mobilization from pre-mobilization data. (A) Mobilization score
derived from the Random Forest algorithm-based ML model vs Day 1 PB CD34 count in G-CSF mobilized donors (N 5 798). (B) Distribution of “poor mobilizer” (Day 1 PB
CD34 cells ,40/mL), “less-than-optimal mobilizer” (Day 1 PB CD34 cells 20-40/mL) and “good-mobilizer” (Day 1 PB CD34 cells .40/mL) based on their mobilization score
calculated by Random Forest based ML model (N 5 798). (C) Confusion matrix, PPV, NPV and accuracy of the prediction in all patients (N 5 799) from the Random
Forest-based model. One hundred twenty-seven out of 171 “poor/less-than-optimal mobilizers” and 536 out of 628 “good mobilizers” were correctly predicted. (D) Mobilization score derived from the AdaBoost algorithm vs Day 1 PB CD34 count in G-CSF mobilized donors (N 5 798). (E) Distribution of “poor mobilizer” (Day 1 PB CD34 count
,40/mL), “less-than-optimal mobilizer” (Day 1 PB CD34 count 20-40/mL) and “good mobilizer” (Day 1 PB CD34 count .40/mL) based on their mobilization score calculated by Adaboost based ML model. (F) Confusion matrix, PPV, NPV and accuracy of the prediction in all patients (N 5 799) from the AdaBoost-based model. 128 out of
171 “poor/less-than-optimal mobilizers” and 531 out of 628 “good mobilizers” were correctly predicted.

Forest-based machine learning model, 127 out of 171 “poor/lessthan-optimal mobilizers” and 536 out of 628 “good mobilizers” were
correctly predicted (positive prediction value [PPV]: 74.3%, negative
prediction value [NPV]: 85.4%, accuracy: 83%). The AdaBoostbased machine learning model showed similar prediction performance, as 128 out of 171 “poor/less-than-optimal mobilizers” and
531 out of 628 “good mobilizers” were correctly predicted (PPV:
74.9%, NPV: 84.6%, accuracy: 82.5%). Together, these machine
learning-based models demonstrated strong predictive power for
predicting donor’s response to G-CSF–induced stem cell
mobilization.

Discussion
G-CSF is currently the standard of care for mobilization and is welltolerated in patients. However, it requires 4 to 5 days of daily
12 APRIL 2022 • VOLUME 6, NUMBER 7

treatment and is associated with side effects such as skeletal pain,
fever, fatigue, nausea, splenic enlargement and rarely, splenic rupture.2 In an effort to ﬁnd more rapid, low-risk mobilization regimens
for donors, the BMT program at Washington University has initiated
a number of phase I/II trials to evaluate novel mobilization strategies.
In this retrospective review, we did a side-by-side comparison of the
mobilization efﬁcacy of G-CSF with three alternative mobilization
strategies, including (1) cytokine-based regimens: GM and GM1G;
(2) CXCR4 antagonist-based regimens: Plerixafor and BL-8040; (3)
combination of GM1P. Based on the CD34 stem cell yield, mobilization strategies involving G-CSF were the most effective mobilization agent, with over 70% of donors achieving the .5 3 106/kg
goal after the ﬁrst LP session. The addition of GM-CSF resulted in
a slight increase of CD34 count/mL, but this was not statistically
signiﬁcant (Figure 1C), despite the signiﬁcantly younger age in this
cohort (Table 1). GM alone has been shown to be a relatively weak
ML-BASED PREDICTION OF STEM CELL MOBILIZATION
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A recent study using the National Marrow Donor Program (NMDP)
dataset found that higher BMI predicts a better stem cell mobilization response to G-CSF. The maximum effective G-CSF dose was
achieved with obese donors, above which higher doses of G-CSF
resulted in no obvious increase in stem cell yield. In contrast,
patients with normal or overweight BMI may beneﬁt from increasing
doses of G-CSF to enhance stem cell yields.22 However, these
increasing doses of G-CSF may also be associated with increased
side effects.2 In our dataset, we have also observed a signiﬁcantly
higher CD34 cell yield in obese donors (Figure 3F). In our G-CSF
data subset (supplemental Table 1), about half of the donors who
had a CD34 count over 40 cells/mL were obese, compared with
27% in donors who had less than 40 cells/mL. The combinational
use of BMI and mobilization score therefore would enable us to narrow down the subset of nonobese, low mobilization score donors
who may beneﬁt from increased G-CSF dosing.
We have previously demonstrated that novel combination therapy
such as G-CSF 1Plerixafor signiﬁcantly improved the efﬁcacy of
stem cell mobilization and yield in cancer patients, which led to the
FDA approval to use this regimen in patients with lymphoma and
multiple myeloma.4,5 However, G-CSF remains the only FDAapproved method for mobilization of allogeneic donors. Donors who
do not mobilize adequate stem cell yield on day 1 of LP may
undergo additional apheresis on day 2. In our dataset, the CD34
yield on day 2 is statistically lower than the day 1 yield (P , .0001,
Wilcoxon Matched-Pairs Signed Ranks Test, supplemental Figure
2). Regardless, there is also the high cost of the Plerixafor treatment
and predictive algorithms to determine the small subset of donors
who may beneﬁt from the new combination therapy have not been
developed yet. Taking the cost of remobilization into account, plerixafor is better and cheaper if used “on-demand” than within a subsequent remobilization in multiple myeloma and lymphoma patients for
autologous stem cell transplantation.23 In some centers, the
“preemptive” strategy based on the PB CD34 count showed some
success to salvage the initial mobilization with G-CSF with the addition of Plerixafor.24 Therefore, we hope that the use of our mobilization score could further improve this clinical need.
The present study demonstrates the use of machine learning as a
prediction tool to assist clinical decision making in the context of PB
mobilization for HSCT. To our knowledge, this is the ﬁrst ML-based
model for stem cell mobilization prediction and one of the largest
single-center datasets for allogeneic stem mobilization. Notably, the
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data used in the prediction modeling were usually acquired 1-2
weeks prior to the mobilization, therefore allowing for early detection
of donors who may have poor or less than optimal stem cell yields.
Compared with the traditional statistical analysis, which is modeldriven, our ML approach shows higher predictability power. In our
parallel analysis of the same dataset using a multivariate logistic
regression model (supplemental Figure 3, supplemental Table 3), an
AUC of 0.74 was achieved, compared with the 0.89 in the ML
approach. However, since the ML model is created from the data
by the algorithms, it is often presented as a “black box” that is less
interpretable as to what the model has learned during the process
and how much each feature contributes to the ﬁnal prediction.25 In
further studies, machine learning algorithms such as Naïve Bayes
(NB) and alternative decision tree (ADTree) that provide interpretable model structure will also be explored.
One limitation of the study is that this is a single-center study
and spans over two decades. While the single-center dataset
showed beneﬁt for our comparison of different mobilization regimens by eliminating inter-center variabilities, for our prediction
model, additional datasets from other centers, the NDMP or
CIBMTR datasets may further improve the accuracy and generalizability of our models. In spite of the signiﬁcant technological
advances in apheresis during the study time, there were minimal
changes in the proportion of good versus poor mobilizers after
the 1995-2000 period, as determined by both the CD34 yield
and PB CD34 count (supplemental Figure 4A-B). Additional
datasets from the above sources in recent years may further
strengthen our study. Another limitation of the study is that while
our prediction model can discriminate most of the donors from
less or over 40 cells/mL CD34 cells, it cannot separate the poor
mobilizer (,20) vs suboptimal mobilizer (between 20 and 40)
due to the small percentage of poor mobilizers in our dataset.
Additional datasets and clinical features will be included in
future studies. More importantly, a similar approach will also be
extended to autologous cancer patients, who have a much
higher failure rate (up to 20%) during the stem cell
mobilization.26
In conclusion, in this study we evaluated the impact of six strategies
for stem cell mobilization. G-CSF-based mobilization strategies were
the most efﬁcient resulting in the highest CD34 cells/mL after 4 to
5 days of G-CSF and in the ﬁrst apheresis collection, while CXCR4
antagonists as a mobilizing strategy results in signiﬁcantly less but
more rapid mobilization in the same day. Using donor demographic
data and baseline laboratory results from the G-CSF mobilized normal donors, we developed ML-based mobilization scoring models
that enable us to predict allogeneic donor response to G-CSF for
stem cell mobilization at the early donor screening stage. The current study provides proof of concept that the ML-based approach
can be used to predict G-CSF–induced stem cell mobilization in
normal allogeneic donors and would serve as a base for the future
validation using other datasets, alternative mobilizing agents
(CXCR4 antagonists) or for similar analyses in patients undergoing
autologous stem cell transplantation.
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mobilizer as a single agent and had to be adjusted to a higher dose
of 15 mg/kg to ensure the minimum 2 3 106/kg goal was met.15
However, the rate of grade II-IV GvHD in recipients was only 13%
from the cells mobilized from GM donors, compared with 49% and
69% from the G-CSF alone and G1GM cohorts, respectively.15 In
contrast to the 4–5 days of cytokine (G-CSF or G1GM) mediated
mobilization, CXCR4 antagonists directly disrupts the interaction of
CXCR4-CXCL12 axis and induces a rapid mobilization of stem and
progenitor cells into peripheral blood within hours. However, as single agents, CXCR4 antagonists mobilize signiﬁcantly fewer CD34
cells/uL than the standard G-CSF approach (Figure 1A,C). Interestingly, BL-8040 mobilizes slightly more CD34 cells compared with
Plerixafor (Figure 1C). This may be explained by prior studies demonstrating that BL-8040 binds to CXCR4 with a higher afﬁnity and
longer CXCR4 occupancy (lower off-rate) compared with
Plerixafor.21
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